BioGeneration Ventures
Paul Da Silva Jardine is an expert in drug development in the cardiovascular field. He is a former VP at Pfizer R & D who spent more than 24 years at Pfizer managing project teams delivering over 50 clinical candidates in cardiovascular, obesity, diabetes, and osteoporosis. He discovered Lasofoxifene and led early clinical development team to an approved compound in Europe. Most recently, he was VP for Research in the Cardiovascular and Metabolic Diseases (CVMED) Research Unit at Pfizer responsible for projects from target identification in the end of Phase 2. After his career at Pfizer, Paul co-founded Staten Biotech (portfolio company of BGV) where is currently the CSO and he is involved in the creation of other BGV portfolio companies.
This person is not in the org chart
This person is not in any offices
BioGeneration Ventures
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.